The U.S. Drug Administration Committee supports the provision of Johnson & Johnson booster shots to all those who have been vaccinated against Johnson & Johnson's new crown vaccine

　　(Fighting against New Coronary Pneumonia) The US Drug Administration Committee supports the provision of Johnson & Johnson's booster shots to all those who have been vaccinated with Johnson & Johnson's new crown vaccine

　　China News Agency, Washington, October 15 (Reporter Sha Hanting) The Expert Committee of the US Food and Drug Administration (FDA) voted on the 15th local time to support the provision of a booster shot of the Johnson & Johnson vaccine to all people who have been vaccinated with a dose of Johnson & Johnson's new crown vaccine.

　　The 19 members of the expert committee voted to support the decision on the same day and recommended a booster shot at least 2 months after the first dose of vaccine.

Currently, the FDA approved the Johnson & Johnson vaccine group for 18 years of age and above.

For Pfizer and Modena vaccine booster, the committee only recommends vaccination for 65 years and older and high-risk groups.

　　In the discussion that day, many experts said that the effective rate of Johnson & Johnson vaccine is obviously not as good as that of Pfizer and Modena vaccines.

A number of research data show that the effective rate of Johnson & Johnson vaccine should be between 50% and 68%.

Some experts believe that Johnson & Johnson's vaccine should also be used as a two-dose vaccine instead of being used as a single-dose vaccine before.

　　Johnson & Johnson said its research shows that a booster shot two months after the first dose of vaccine can increase the effective rate from 70% to 94%.

　　Regarding the data provided by Johnson & Johnson, many experts believe that although the data is not sufficient, they should still support vaccination with booster shots to improve vaccine protection.

　　Next, the FDA will decide whether to approve the use of Johnson & Johnson's new crown vaccine booster.

The FDA usually follows the opinions of its expert committees.

　　At present, the FDA has approved the provision of Pfizer vaccine booster shots to the elderly and high-risk groups.

On the 14th, the FDA expert committee has supported the provision of a booster shot of the Modena vaccine to the elderly and high-risk groups.

　　According to statistics, at present, more than 188 million people in the United States have been vaccinated against the new crown, most of which have been vaccinated by Pfizer or Modena, and only 15 million people have been vaccinated against Johnson & Johnson.

(over)